<DOC>
	<DOCNO>NCT00039520</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine sulindac docetaxel treat woman metastatic recurrent breast cancer .</brief_summary>
	<brief_title>Sulindac Docetaxel Treating Women With Metastatic Recurrent Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate woman metastatic recurrent adenocarcinoma breast treat sulindac docetaxel . - Determine time progression patient treat regimen . - Determine toxicity regimen patient . OUTLINE : Patients receive oral sulindac twice daily . Patients also receive docetaxel IV 1 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow within 3-4 week . PROJECTED ACCRUAL : Approximately 12-33 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma breast Metastatic recurrent disease Measurable disease Bone disease eligible No hematologic malignancy No carcinomatous meningitis and/or untreated uncontrolled brain parenchymal disease At least 8 week since prior therapy brain parenchymal disease patient must asymptomatic CNS disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Premenopausal postmenopausal Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) One following : SGOT SGPT great 2.5 time ULN AND Alkaline phosphatase great ULN OR SGOT SGPT great ULN AND Alkaline phosphatase great 4 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No unstable angina No uncontrolled atrial ventricular arrhythmia No congestive heart failure No uncontrolled hypertension Other : No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer , carcinoma situ cervix , contralateral breast cancer No active unresolved infection No poorly control diabetes mellitus No prior hypersensitivity reaction sulindac Polysorbate 80 No peripheral neuropathy grade 2 great No active peptic ulcer disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy No concurrent biological response modifier No concurrent trastuzumab ( Herceptin ) Chemotherapy : No 1 prior chemotherapy regimen adjuvant set No 1 prior chemotherapy regimen recurrent metastatic disease No prior docetaxel Prior paclitaxel allow At least 1 week since prior chronic sulindac At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent sulindac No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Surgery : Not specify Other : At least 1 week since prior antibiotic At least 4 week since prior investigational agent No concurrent investigational drug No concurrent antineoplastic therapy No concurrent chronic ( full dose 2 week ) nonsteroidal antiinflammatory drug ( except ibuprofen naproxen sodium ) , include cyclooxygenase2 inhibitor salicylate ( e.g. , aspirin , mesalamine , azodisalicylate , salsalate , sulfasalazine ) No concurrent parenteral antibiotic Concurrent lowdose aspirin cardiovascular prevention allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>